Davy James, Managing Editor

Antiretroviral drug interactions now included due to high prevalence of HIV coinfection among patients with hepatitis C virus.

Daratumumab is a single agent for multiple myeloma in patients who previously received at least 3 lines of therapy.

Study finds many silver plans have higher out-of-pocket costs for most the commonly prescribed HIV treatments.

Approval sought for Imbruvica combination for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Marc O'Connor, chief operating officer of Curant Health, discusses counseling patients on a therapeutic regimen for IBD.

Clostridium sporogenes bacteria able to eradicate colon cancer tumor cells.

Modified version of Adynovate lasts longer in the blood for less frequent injections.

HIV drug Tenofovir may carry a risk of nephrotoxicity.

Top stories of the week on Specialty Pharmacy Times.

Osimertinib (Tagrisso) is a once daily tablet for patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.

Treatment with sarilumab improves RA signs, symptoms, and physical function.

Patients simultaneously registering at multiple centers had higher transplant rates, lower death rates waiting for a transplant, and greater income.

Cosentyx found to maintain improvements in joint and skin disease, physical function, and quality of life in PsA patients.

Patients with cancer see a decline in employment, hours worked, individual income, and total family income following diagnosis.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the development of medical marijuana within the specialty space.

HCV drug combination may cut treatment time by 75%.

Combination of Cotellic and Zelboraf shows superior overall and progression free survival in melanoma treatment.

Newly discovered pathway may prove effective target for treatment of triple-negative breast cancer.

Once-a-week treatment is the first oral proteasome inhibitor to reach late stage clinical development.

Michael Zeglinski, vice president of Specialty Pharmacy Operations at BriovaRx, discusses the alignment between specialty pharmacies and ACOs.

Benefits of Plavix found to outweigh potential adverse events.

Serum levels may determine impact of anti-tumor necrosis factor drugs.

Study may lead to vaccines that force an immune response.

Researchers seek to determine which side effects will be experienced by different patient groups.

Top stories of the week on Specialty Pharmacy Times.

David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses how the ACA has impacted the specialty landscape.

Gilead's Genvoya is the first TAF-based regimen approved by the FDA.

Terms like revolutionary or miracle cause confusion for readers.

Biofilm proteins show promise in treatment of gastrointestinal disorders.

Nucala is for use with other asthma drugs for the maintenance of patients 12 years and older.